Friday, May 16th, 2014

Symptelligence Partners with LABORIE to Launch weShare Worldwide

• weShare Unveiled by Dr. Jerry Blaivas at 2014 AUA Annual Meeting
• New Mobile and Web Application Provides Quantifiable Data to Improve Patient Diagnosis and Urinary Health
weshare mobile app urologie aua meeting
ORLANDO, Fla. (May 16, 2014) – Symptelligence co-founder Dr. Jerry Blaivas today announced a partnership with LABORIE – the leading global developer and manufacturer of innovative medical devices for urologic health – to launch weShare worldwide.

weShare – a new Web and smartphone application designed to improve treatment, decision-making and communication between patients and urologists – will be unveiled to the medical community at the 2014 American Urological Association Annual Meeting in Orlando, Fla.

“weShare gives urologists quantifiable insight into a patient’s condition at a level we simply have not had before,” said Dr. Blaivas, MD, FACS. “The tool provides physicians with standardized data quantifying patients’ symptoms, pain levels and other metrics before they even walk into the exam room with the patient.”

Patients use the app to generate a weScore prior to visiting their urologist. weScores quantify the patient’s urinary health and are automatically available for physicians to view online. Via a secure login on the weShare website, physicians access data visualizations that help them monitor patients’ health over time.

A weScore combines patient responses to a proprietary questionnaire, a 24-hour urination diary, the American Urological Association Symptoms Score (AUASS) and other standardized scoring methods. Dr. Blaivas created the weScore algorithm based on more than three decades of experience as a practicing urologist and researcher.

Symptelligence’s launch of weShare marks a notable leap from current intake forms and subjective conversation methods that physicians use today and enables both doctors and patients to ascertain a more accurate understanding of treatment outcomes and overall urinary health.

About Symptelligence

Founded in 2012 by Blavias and Stuart Smyth, Symptelligence specializes in intelligent and integratable patient data and disease management solutions. Smyth, CEO, is a medical entrepreneur with 25 years’ experience building and leading both medical device and diagnostic systems/software companies and a former VP at LABORIE. Blaivas, Clinical Professor of Urology at Weill Cornell Medical College, Adjunct Professor at SUNY Downstate and Attending Surgeon at New York Presbyterian Hospital and Lenox Hill Hospital, is an internationally renowned urologist with more than 30 years of clinical experience and serves as Symptelligence’s Chief Scientific and Data Operations Officer. Known as a “doctor’s doctor,” Blavias is considered the “doctor of last resort” when patients experience multiple failed treatments.